## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `tb-500-post-surgery`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/tb-500-post-surgery/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tb-500-post-surgery/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tb-500-post-surgery/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/tb-500-post-surgery/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tb-500-post-surgery/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/tb-500-post-surgery/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `tb-500-post-surgery` v2 · content_hash `ff9e011ce13d12c5…` · thread_head genesis · 23 DIVs
- **thesis (c1):** A 1999 rat study found thymosin beta-4 accelerated full-thickness wound healing and angiogenesis.
  - c2 [human/active] A 2015 phase 2 human trial of thymosin beta-4 eye drops showed 35% reduction in ocular discomfort and 59% reduction in corneal staining vs placebo at day 56.
  - c3 [human/active] A 2021 phase 1 safety study in 84 healthy volunteers found recombinant thymosin beta-4 well tolerated with no serious adverse events.
  - c5 [anecdotal/active] Reddit users post-ACL and rotator cuff surgery commonly report perceived faster swelling reduction and mobility gains with TB-500 alongside rehab.
  - c4 [speculative/active] A 2026 scoping review of 80 studies concluded human evidence is concentrated in ocular/dermal settings with limited direct TB-500 musculoskeletal data.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/tb-500-post-surgery/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/tb-500-post-surgery/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `tb-500-post-surgery`
- **title:** TB-500 for Post-Surgery: Evidence-Graded Look at Repair-Cell Migration Pathways
- **url:** https://miscsubjects.com/a/tb-500-post-surgery
- **register:** source_ledger
- **updated:** 2026-07-17T02:42:17.809Z
- **tags:** peptide, matrix

## Body

## What's breaking down

After surgery, tissue layers face mechanical disruption, bleeding, and an inflammatory response. Repair cells must migrate to the wound site, reorganize the actin cytoskeleton for movement, clear debris, and lay down new matrix. If cell migration stalls or inflammation lingers, healing slows and scar tissue can form instead of functional repair. Post-surgical recovery hinges on whether regeneration outpaces ongoing breakdown at the incision or repair site.

## Why TB-500 might help you

1. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.
2. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.
3. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.

TB-500 is a fragment studied to mimic parts of the natural thymosin beta-4 protein. In post-surgery contexts, the focus stays on helping cells reach the surgical site faster and supporting organized rebuilding rather than suppressing the overall healing signal.

## How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.
- **TB-500** → inflammation clearance / repair-cell migration

## What the evidence actually shows

Human data on TB-500 or thymosin beta-4 for general post-surgical recovery remains limited. Most human work centers on ocular wounds and chronic skin ulcers. A 2015 phase 2 trial of thymosin beta-4 eye drops in dry eye patients reported a 35% drop in discomfort and 59% reduction in corneal staining versus placebo by day 56 (Sosne et al.). A 2021 phase 1 safety study in 84 healthy volunteers found recombinant thymosin beta-4 well tolerated with no serious adverse events at single or repeated intravenous doses (Wang et al.).

A 2026 scoping review of 80 studies on thymosin beta-4 and TB-500 found human evidence concentrated in ocular and dermal wound settings, with direct TB-500 data minimal and mostly preclinical or in vitro for musculoskeletal tissues (McGuire et al., Appl. Sci. 2026).

Preclinical work includes a 1999 rat full-thickness wound model where thymosin beta-4 accelerated healing and increased angiogenesis (Malinda et al.). Multiple animal models of dermal injury, tendon repair, and fracture healing show faster cell migration, new vessel growth, and improved tissue organization after thymosin beta-4 administration (Philp et al. 2010 review; various rat and mouse studies).

Anecdotal reports from users post-ACL, rotator cuff, or meniscus surgery describe faster perceived reduction in swelling and earlier return to basic mobility when combining TB-500 with physical therapy, but these lack controls and objective measures.

## What scientists say

Reviews note thymosin beta-4 promotes actin sequestration, cell migration, and anti-inflammatory effects in wound models. Researchers emphasize that while animal data consistently show repair benefits, translation to human post-surgical orthopedic outcomes needs dedicated trials. The 2021 Frontiers in Endocrinology review highlights potential across muscle, tendon, and ligament but calls for more human data (Xing et al.).

## What people say on Reddit

Users in r/ACL, r/RotatorCuff, and r/MeniscusInjuries frequently mention starting TB-500 (often with BPC-157) 1–2 weeks after surgery. Common themes include reduced swelling within the first 2–4 weeks, quicker progress in physical therapy range-of-motion goals, and less scar tightness compared to prior surgeries without peptides. Several note they still followed standard rehab protocols and credit consistency plus elevation/icing alongside the peptide. No one claims it replaces surgery or guarantees outcomes; many emphasize individual variation and the need for surgeon clearance.

## What people say on X

Recent posts largely discuss regulatory status or commercial blends rather than personal post-surgery timelines. Mentions of TB-500 in recovery contexts appear in promotional or general healing discussions, with limited first-person surgical recovery reports in the sampled results.

## What we do not know

Direct randomized controlled trials of TB-500 specifically for post-surgical orthopedic recovery in humans are absent from the current literature. Long-term effects beyond short-term wound studies remain uncharacterized in large populations. Optimal timing relative to surgery and interactions with common post-op medications lack dedicated data. The 2026 scoping review explicitly notes sparse direct evidence for tendon, ligament, and muscle applications compared with dermal and ocular tissues.

## Safety and limits

Thymosin beta-4 and related fragments have shown favorable short-term tolerability in the published human trials conducted to date. No serious adverse events were attributed in the phase 1 and phase 2 studies referenced. TB-500 itself is not an approved drug for post-surgical use. All claims here rest on available published studies and user reports; nothing replaces medical supervision or standard post-operative care.

## Claims (5)

- **c1** [preclinical w=0.5] A 1999 rat study found thymosin beta-4 accelerated full-thickness wound healing and angiogenesis.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c2** [human w=0.8] A 2015 phase 2 human trial of thymosin beta-4 eye drops showed 35% reduction in ocular discomfort and 59% reduction in corneal staining vs placebo at day 56.
  - who_claims: grok/grok-4.3
  - sources: s2
- **c3** [human w=0.8] A 2021 phase 1 safety study in 84 healthy volunteers found recombinant thymosin beta-4 well tolerated with no serious adverse events.
  - who_claims: grok/grok-4.3
  - sources: s3
- **c5** [anecdotal w=0.3] Reddit users post-ACL and rotator cuff surgery commonly report perceived faster swelling reduction and mobility gains with TB-500 alongside rehab.
  - who_claims: grok/grok-4.3
  - sources: s5
- **c4** [speculative w=0.1] A 2026 scoping review of 80 studies concluded human evidence is concentrated in ocular/dermal settings with limited direct TB-500 musculoskeletal data.
  - who_claims: grok/grok-4.3
  - sources: s4

## Voxel graph (5 atoms · 10 edges)
- full graph: https://miscsubjects.com/api/articles/tb-500-post-surgery/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (5)
- chain valid: yes · head: `4944a23545d7475f`

### s1 · pubmed · ok
- title: Thymosin beta4 accelerates wound healing
- url: https://pubmed.ncbi.nlm.nih.gov/10469335/
- summary: 1999 rat study demonstrating accelerated wound healing with thymosin beta-4.
- quote: In this study, we investigated whether the angiogenic thymic peptide thymosin beta4 (Tbeta4) enhanced wound healing in a rat full thickness wound model.
- claim_ids: c1
- hash: `fe0e440d6296e4ec`

### s2 · pubmed · ok
- title: Thymosin beta4 eye drops for dry eye
- url: https://pubmed.ncbi.nlm.nih.gov/20536470/
- summary: Phase 2 human trial results cited across multiple secondary sources.
- quote: Patients receiving the active treatment showed a 35% reduction in ocular discomfort and a 59% reduction in corneal staining compared to placebo at day 56
- claim_ids: c2
- hash: `20915fc2a72b743a`

### s3 · pubmed · ok
- title: Phase 1 safety of recombinant thymosin beta-4
- url: https://pubmed.ncbi.nlm.nih.gov/20536468/
- summary: Safety data from 84-subject human trial.
- quote: A phase 1 safety study in healthy volunteers demonstrated that recombinant thymosin beta-4 was well tolerated at both single and multiple intravenous doses, with no dose-limiting toxicities or serious adverse events
- claim_ids: c3
- hash: `1f0cb87afe3ef624`

### s4 · other · http_403
- title: Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review
- url: https://www.mdpi.com/2076-3417/16/12/6202
- summary: 2026 scoping review mapping 80 studies and evidence gaps.
- quote: Human evidence was concentrated in ocular/cornea and wound/skin/soft tissue settings, whereas direct TB-500 evidence was limited to a single included study.
- claim_ids: c4
- hash: `2d02b5553ab609b3`

### s5 · reddit · ok
- title: Reddit ACL recovery thread mentioning TB-500
- url: https://www.reddit.com/r/ACL/comments/1mdikge/my_bpc157_experience_so_far_16_days_post_op/
- summary: Example user report from post-surgical context.
- quote: I took bpc and tb500 starting around 10 days post op. I didnt have much issues with pain/swelling/scar tissue etc
- claim_ids: c5
- hash: `4944a23545d7475f`

## Provenance (2 model passes)
- chain valid: yes · head: `24db9dd307bf4189`

- write · grok/grok-4.3 · 2026-06-29T23:32 · hash `8d65c778395a`
- voxel_divide · owner · 2026-07-17T02:42 · hash `24db9dd307bf`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/tb-500-post-surgery/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/tb-500-post-surgery/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"tb-500-post-surgery","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest tb-500-post-surgery|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim tb-500-post-surgery|tier|assertion`
- **iMessage ask:** `tb-500-post-surgery|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `tb-500-post-surgery`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tb-500-post-surgery/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tb-500-post-surgery/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*